,address1,address2,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA', 'age': 62, 'title': 'Chief Exec. Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 635000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
1,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Ms. Mali  Zeevi CPA, CPA', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 380000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
2,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Dr. Ella  Sorani', 'age': 54, 'title': 'Chief Devel. Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 457000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
3,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Ms. Holly W. May M.B.A.', 'age': 60, 'title': 'Pres of BioLineRx USA', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 328000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
4,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Mr. John  Lacey', 'title': 'Head of Corp. Communications & Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
5,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Mr. Adam  Janoff Esq.', 'title': 'Gen. Counsel & Head of Compliance', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
6,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Ms. Tsipi  Keren-Lehrer B.Sc., L.L.B.', 'title': 'Head of BD & Strategic Advisor', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
7,Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,7177871,Israel,972 8 642 9100,972 8 642 9101,https://www.biolinerx.com,Biotechnology,Healthcare,"BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.",49,"{'maxAge': 1, 'name': 'Mr. Raziel  Fried', 'title': 'Treasurer & Budgetary Control Director', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.76,1.89,1.88,2.05,1.76,1.89,1.88,2.05,0.0,1.245345,-195.00002,2363367,2363367,1031120,3881850,3881850,1.91,1.95,900,1200,119984672,0.55,2.53,1.6128,1.1349,0.0,0.0,USD,100706664,0.0,61245709,61530600,2398529,2133705,1690761600,1693440000,0.039,0.0,0.05243,3.7,0.345,5.652174,1672444800,1703980800,1688083200,-43285000,-0.7,-0.01,0.08,1:15,1563148800,-2.987,NCM,EQUITY,BLRX,BLRX,BioLineRx Ltd.,BioLineRx Ltd.,1311773400,America/New_York,EDT,-14400000,1.95,19.0,7.0,13.0,13.0,2.0,buy,2,32815000,0.533,-33719000,13537000,2.647,2.787,64.296,-0.33768,-1.11528,-21090500,-32063000,0.0,0.0,0.0,USD,
